Literature DB >> 22491736

A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease.

Maria Cuzzola1, Maurizio Fiasché, Pasquale Iacopino, Giuseppe Messina, Massimo Martino, Giuseppe Console, Roberta Fedele, Daniela Massi, Anna Grazia Recchia, Giuseppe Irrera, Fortunato Morabito.   

Abstract

BACKGROUND: Acute graft-versus-host disease is a severe complication of allogeneic stem cell transplantation in which the functional immune cells of the donor recognize the recipient as foreign and mount an immunological attack. There is an urgent need for better diagnostic instruments for the assessment of acute graft-versus-host disease. In the present study, a novel bioinformatics framework was used to identify gene expression patterns associated with acute graft-versushost disease in patients undergoing allogeneic hematopoietic stem cell transplantation. DESIGN AND METHODS: Peripheral blood cells were collected prospectively from patients who did develop acute graftversus-host disease (YES) and from those who did not (NO). Gene expression profiling was performed using a panel of 47 candidate genes potentially involved in alloreactive responses. The entire population of YES/NO acute graft-versus-host disease patients formed the experimental validation set. Personalized modeling based on a gene selection technique was applied to identify the most significant mRNA transcripts, which were then used to profile individual data samples for training and testing the classification/prediction framework.
RESULTS: A leave-one-out cross-validation procedure was performed to investigate the robustness of the classification framework producing the following results: 100% on the training dataset and 97% on the testing dataset. According to our integrated methodology, transcripts for FOXP3, ICOS, CD52 and CASP1, genes involved in immune alloreactive responses and participating in immune cell interactions, were identified as the most informative biomarkers in allogeneic stem cell transplant recipients experiencing acute graft-versus-host disease.
CONCLUSIONS: This study demonstrates that the integrated methodology proposed is useful for the selection of valid gene targets for the diagnosis of acute graft-versus-host disease, producing satisfactory accuracy over independent clinical features of the allogeneic transplanted population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22491736      PMCID: PMC3507302          DOI: 10.3324/haematol.2011.059980

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  22 in total

1.  Biomarkers of immune activation to screen for severe, acute GVHD.

Authors:  K J August; K-Y Chiang; R M Bostick; W D Flanders; E K Waller; A Langston; D Worthington-White; P Rowland; K F Moore; H J Khoury; J T Horan
Journal:  Bone Marrow Transplant       Date:  2010-07-12       Impact factor: 5.483

2.  Elafin is a biomarker of graft-versus-host disease of the skin.

Authors:  Sophie Paczesny; Thomas M Braun; John E Levine; Jason Hogan; Jeffrey Crawford; Bryan Coffing; Stephen Olsen; Sung W Choi; Hong Wang; Vitor Faca; Sharon Pitteri; Qing Zhang; Alice Chin; Carrie Kitko; Shin Mineishi; Gregory Yanik; Edward Peres; David Hanauer; Ying Wang; Pavan Reddy; Samir Hanash; James L M Ferrara
Journal:  Sci Transl Med       Date:  2010-01-06       Impact factor: 17.956

Review 3.  Pathogenesis and management of graft-versus-host disease.

Authors:  Sung W Choi; John E Levine; James L M Ferrara
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

Review 4.  The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.

Authors:  Alessandro Busca
Journal:  Expert Opin Biol Ther       Date:  2011-03-11       Impact factor: 4.388

Review 5.  Plasma biomarkers in graft-versus-host disease: a new era?

Authors:  Sophie Paczesny; John E Levine; Thomas M Braun; James L M Ferrara
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 6.  New perspectives on the biology of acute GVHD.

Authors:  S Paczesny; D Hanauer; Y Sun; P Reddy
Journal:  Bone Marrow Transplant       Date:  2009-11-30       Impact factor: 5.483

7.  Advances in the clinical management of GVHD.

Authors:  James L M Ferrara
Journal:  Best Pract Res Clin Haematol       Date:  2008-12       Impact factor: 3.020

Review 8.  Acute graft-versus-host disease: from the bench to the bedside.

Authors:  Gerard Socié; Bruce R Blazar
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

9.  Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells.

Authors:  Jason E Foley; Jacopo Mariotti; Kaitlyn Ryan; Michael Eckhaus; Daniel H Fowler
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

10.  Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.

Authors:  Tara L Spivey; Lorenzo Uccellini; Maria Libera Ascierto; Gabriele Zoppoli; Valeria De Giorgi; Lucia Gemma Delogu; Alyson M Engle; Jaime M Thomas; Ena Wang; Francesco M Marincola; Davide Bedognetti
Journal:  J Transl Med       Date:  2011-10-12       Impact factor: 5.531

View more
  2 in total

1.  Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model.

Authors:  Aude Burlion; Simon Brunel; Nicolas Y Petit; Daniel Olive; Gilles Marodon
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

Review 2.  Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes.

Authors:  Rihab Gam; Pranali Shah; Rachel E Crossland; Jean Norden; Anne M Dickinson; Ralf Dressel
Journal:  Front Immunol       Date:  2017-04-03       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.